Literature DB >> 11079776

Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies.

L Minghetti1, A Greco, F Cardone, M Puopolo, A Ladogana, S Almonti, C Cunningham, V H Perry, M Pocchiari, G Levi.   

Abstract

The levels of 2 arachidonic acid metabolites formed either by enzymatic activity of cyclooxygenase, i.e. prostaglandin E2 (PGE2), or by free radical-catalyzed peroxidation, i.e. F2-isoprostane 8-epi-prostaglandin F2alpha (8-epi-PGF2alpha), were measured in the CSF of subjects with sporadic and familial Creutzfeldt-Jakob disease (CJD) and in brain homogenates of scrapie-infected mice. The CSF levels of both metabolites were increased in sporadic CJD (n = 52) and familial CJD (n = 10) patients when compared with a group of patients with noninflammatory disorders. Similarly, PGE2 and 8-epi-PGF2alpha levels were higher in brain homogenates obtained from C57BL/6J mice infected with the ME7 scrapie strain than in brain homogenates from control animals. As PGE2 is 1 of the most abundant prostaglandins released during inflammation and 8-epi-PGF2alpha is a quantitative marker of lipid peroxidation, our results provide in vivo biochemical evidence for the occurrence of inflammation and oxidative stress in human and experimental transmissible spongiform encephalopathies (TSEs), a concept so far based mainly on histopathological and in vitro evidence. Interestingly, in sporadic CJD patients, high CSF levels of PGE2, but not 8-epi-PGF2alpha, correlated with short survival time, suggesting that the inflammatory response correlates with the clinical duration of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079776     DOI: 10.1093/jnen/59.10.866

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  19 in total

Review 1.  Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction.

Authors:  Roberta De Simone; Maria Antonietta Ajmone-Cat; Luisa Minghetti
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 2.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Authors:  P J Cimino; C Dirk Keene; Richard M Breyer; Kathleen S Montine; Thomas J Montine
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

3.  Accelerated prion disease in the absence of interleukin-10.

Authors:  Alana M Thackray; Andrew N McKenzie; Michael A Klein; Angus Lauder; Raymond Bujdoso
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.

Authors:  M Combrinck; J Williams; M A De Berardinis; D Warden; M Puopolo; A D Smith; L Minghetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06-08       Impact factor: 10.154

Review 5.  Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity.

Authors:  Erik S Musiek; Ginger L Milne; BethAnn McLaughlin; Jason D Morrow
Journal:  Brain Pathol       Date:  2005-04       Impact factor: 6.508

6.  Genomic and post-genomic analyses of human prion diseases.

Authors:  Maurizio Pocchiari; Anna Poleggi; Serena Principe; Silvia Graziano; Franco Cardone
Journal:  Genome Med       Date:  2009-06-22       Impact factor: 11.117

Review 7.  Electrophilic cyclopentenone isoprostanes in neurodegeneration.

Authors:  Erik S Musiek; Bethann McLaughlin; Jason D Morrow
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

8.  Scavenging of highly reactive gamma-ketoaldehydes attenuates cognitive dysfunction associated with epileptogenesis.

Authors:  Jennifer N Pearson; Eric Warren; Li-Ping Liang; L Jackson Roberts; Manisha Patel
Journal:  Neurobiol Dis       Date:  2016-12-05       Impact factor: 5.996

9.  Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Authors:  Clive Bate; Mourad Tayebi; Luisa Diomede; Mario Salmona; Alun Williams
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

10.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.